SCHEDULE 13G 0001863769 XXXXXXXX LIVE Common Stock, $0.00001 par value per share 05/16/2025 0001501796 Aura Biosciences, Inc. 05153U107 80 Guest Street Boston MA 02135 Rule 13d-1(c) Frazier Life Sciences Public Fund, L.P. DE 0.00 3855722.00 0.00 3855722.00 3855722.00 6.1 PN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. DE 0.00 3855722.00 0.00 3855722.00 3855722.00 6.1 PN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.L.C. DE 0.00 3855722.00 0.00 3855722.00 3855722.00 6.1 OO The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Frazier Life Sciences Public Overage Fund, L.P. DE 0.00 1137454.00 0.00 1137454.00 1137454.00 1.8 PN The shares listed in rows 6, 8 and 9 consist of (i) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP Overage, L.P. DE 0.00 1137454.00 0.00 1137454.00 1137454.00 1.8 PN The shares listed in rows 6, 8 and 9 consist of (i) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP Overage, L.L.C. DE 0.00 1137454.00 0.00 1137454.00 1137454.00 1.8 OO The shares listed in rows 6, 8 and 9 consist of (i) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Frazier Life Sciences X, L.P. DE 0.00 159155.00 0.00 159155.00 159155.00 0.3 PN The shares listed in rows 6, 8 and 9 consist of (i) 128,520 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS X, L.P. DE 0.00 159155.00 0.00 159155.00 159155.00 0.3 PN The shares listed in rows 6, 8 and 9 consist of (i) 128,520 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS X, L.L.C. DE 0.00 159155.00 0.00 159155.00 159155.00 0.3 OO The shares listed in rows 6, 8 and 9 consist of (i) 128,520 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Frazier Life Sciences XI, L.P. DE 0.00 423782.00 0.00 423782.00 423782.00 0.7 PN The shares listed in rows 6, 8 and 9 consist of (i) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. DE 0.00 423782.00 0.00 423782.00 423782.00 0.7 PN The shares listed in rows 6, 8 and 9 consist of (i) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.L.C. DE 0.00 423782.00 0.00 423782.00 423782.00 0.7 OO The shares listed in rows 6, 8 and 9 consist of (i) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Frazier Life Sciences XII, L.P. b DE 0.00 739565.00 0.00 739565.00 739565.00 1.2 PN The shares listed in rows 6, 8 and 9 consist of (i) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XII, L.P. DE 0.00 739565.00 0.00 739565.00 739565.00 1.2 PN The shares listed in rows 6, 8 and 9 consist of (i) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XII, L.L.C. DE 0.00 739565.00 0.00 739565.00 739565.00 1.2 OO The shares listed in rows 6, 8 and 9 consist of (i) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025 and (iii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. James N. Topper X1 0.00 6315678.00 0.00 6315678.00 6315678.00 9.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iii) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (v) 128,520 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (vii) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (ix) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025, (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (v) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (vi) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, and (vii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Patrick J. Heron X1 0.00 6315678.00 0.00 6315678.00 6315678.00 9.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iii) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (v) 128,520 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (vii) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (ix) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025, (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (v) 30,635 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (vi) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, and (vii) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Albert Cha X1 0.00 4993176.00 0.00 4993176.00 4993176.00 7.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iii) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025, (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, and (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. James Brush X1 0.00 4993176.00 0.00 4993176.00 4993176.00 7.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 3,113,550 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iii) 918,510 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025, (iii) 742,172 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, and (iv) 218,944 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Daniel Estes X1 0.00 1163347.00 0.00 1163347.00 1163347.00 1.9 IN The shares listed in rows 6, 8 and 9 consist of (i) 342,210 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (ii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, (iii) 597,210 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (iv) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P. The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025, (iii) 81,572 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025, and (iv) 142,355 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to pre-funded warrants exercisable within 60 days of May 16, 2025. Aura Biosciences, Inc. 80 Guest Street, Boston, MA, 02135. The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members") The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304 Entities: FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLSPOF - Delaware, U.S.A. FHMLSP Overage, L.P. - Delaware, U.S.A. FHMLSP Overage, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C. - Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen Cha - United States Citizen Brush - United States Citizen Estes - United States Citizen Y The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of Topper's and Heron's cover pages have been rounded down from 9.99% to 9.9%. The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference. The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference. The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement. Frazier Life Sciences Public Fund, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLSP, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLSP, L.L.C. /s/ Steve R. Bailey 05/23/2025 Frazier Life Sciences Public Overage Fund, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLSP Overage, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLSP Overage, L.L.C. /s/ Steve R. Bailey 05/23/2025 Frazier Life Sciences X, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLS X, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLS X, L.L.C. /s/ Steve R. Bailey 05/23/2025 Frazier Life Sciences XI, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLS XI, L.P. /s/ Steve R. Bailey 05/23/2025 FHMLS XI, L.L.C. /s/ Steve R. Bailey 05/23/2025 Frazier Life Sciences XII, L.P. /s/ Gordon Empey 05/23/2025 FHMLS XII, L.P. /s/ Gordon Empey 05/23/2025 FHMLS XII, L.L.C. /s/ Gordon Empey 05/23/2025 James N. Topper /s/ Steve R. Bailey 05/23/2025 Patrick J. Heron /s/ Steve R. Bailey 05/23/2025 Albert Cha /s/ Steve R. Bailey 05/23/2025 James Brush /s/ Steve R. Bailey 05/23/2025 Daniel Estes /s/ Steve R. Bailey 05/23/2025